BRPI0923675A2 - formulação para administração de medicamento com baixa quantidade de lipídeos por via transmucosal oral - Google Patents

formulação para administração de medicamento com baixa quantidade de lipídeos por via transmucosal oral

Info

Publication number
BRPI0923675A2
BRPI0923675A2 BRPI0923675A BRPI0923675A BRPI0923675A2 BR PI0923675 A2 BRPI0923675 A2 BR PI0923675A2 BR PI0923675 A BRPI0923675 A BR PI0923675A BR PI0923675 A BRPI0923675 A BR PI0923675A BR PI0923675 A2 BRPI0923675 A2 BR PI0923675A2
Authority
BR
Brazil
Prior art keywords
lipid
formulation
drug administration
lowering drug
oral transmucosal
Prior art date
Application number
BRPI0923675A
Other languages
English (en)
Inventor
Marc Maury
Philippe Perovitch
Original Assignee
Marc Maury
Philippe Perovitch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marc Maury, Philippe Perovitch filed Critical Marc Maury
Publication of BRPI0923675A2 publication Critical patent/BRPI0923675A2/pt
Publication of BRPI0923675A8 publication Critical patent/BRPI0923675A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0923675A 2008-12-22 2009-12-17 formulação para a administração de hipolipemiantes por via transmucosa oral BRPI0923675A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0858947A FR2940116B1 (fr) 2008-12-22 2008-12-22 Formulation pour l'administration d'hypolipemiant par voie trans-muqueuse buccale
PCT/FR2009/052591 WO2010072950A1 (fr) 2008-12-22 2009-12-17 Formulation pour l'administration d'hypolipemiants par voie trans-muqueuse buccale

Publications (2)

Publication Number Publication Date
BRPI0923675A2 true BRPI0923675A2 (pt) 2016-01-19
BRPI0923675A8 BRPI0923675A8 (pt) 2018-05-29

Family

ID=40872056

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0923675A BRPI0923675A8 (pt) 2008-12-22 2009-12-17 formulação para a administração de hipolipemiantes por via transmucosa oral

Country Status (9)

Country Link
US (1) US8889663B2 (pt)
EP (1) EP2379054A1 (pt)
JP (1) JP5529165B2 (pt)
CN (1) CN102264346A (pt)
BR (1) BRPI0923675A8 (pt)
FR (1) FR2940116B1 (pt)
MX (1) MX2011006797A (pt)
RU (1) RU2528897C2 (pt)
WO (1) WO2010072950A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2906140B1 (fr) * 2006-09-22 2008-12-05 Philippe Perovitch Forme galenique pour l'administration par voie trans-muqueuse de principes actifs
GB2497728A (en) * 2011-12-14 2013-06-26 Londonpharma Ltd Statin formulations for transmucosal delivery
FR3000896B1 (fr) * 2013-01-14 2016-08-26 Philippe Perovitch Forme galenique pour l'administration de principe(s) actif(s) permettant l'induction acceleree du sommeil et/ou le traitement des troubles du sommeil
FR3031668A1 (fr) 2015-01-20 2016-07-22 Philippe Perovitch Dispositif d'administration d'un principe actif par voie per-muqueuse buccale.
FR3053244A1 (fr) 2016-07-01 2018-01-05 Philippe Perovitch Dispositif d'administration d'au moins un principe actif par voie per-muqueuse buccale.
US20260027048A1 (en) * 2022-06-03 2026-01-29 Polaryx Therapeutics, Inc. Gemfibrozil formulation
CN116270507A (zh) * 2023-03-02 2023-06-23 青岛海洋生物医药研究院股份有限公司 一种含脂蛋白脂酶刺激剂的舌下含片及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5582838A (en) * 1994-12-22 1996-12-10 Merck & Co., Inc. Controlled release drug suspension delivery device
US20030077229A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
US20030095925A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders
DE19929197A1 (de) * 1999-06-25 2000-12-28 Novosis Pharma Ag Transdermalsysteme zur Abgabe von 5-HT3-Rezeptor-Antagonisten und ihre Verwendung zur antiemitischen Behandlung
US20070225379A1 (en) * 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
US7033612B2 (en) * 2003-01-03 2006-04-25 Kang David S Composition and method for treating age-related disorders
JP2004231603A (ja) * 2003-01-31 2004-08-19 Hideji Watanabe コエンザイムｑ１０を主成分とする口腔内塗布剤及びその製造方法
US20050281868A1 (en) * 2004-06-21 2005-12-22 Fairfield Clinical Trials, Llc Transdermal delivery system for statin combination therapy
BRPI0501708A (pt) * 2005-05-10 2007-05-02 Jean Marc Millet dispositivo de liberação lenta por processo transdérmico de um medicamento contra o excesso de colesterol e método de produção de um dispositivo transdérmico
CN1778296B (zh) * 2005-07-19 2010-04-14 淮北辉克药业有限公司 他汀类药物的长效制剂
FR2906140B1 (fr) * 2006-09-22 2008-12-05 Philippe Perovitch Forme galenique pour l'administration par voie trans-muqueuse de principes actifs
US20080249120A1 (en) * 2006-11-22 2008-10-09 Glenmark Pharmaceuticals Limited Pharmaceutical compositions
FR2910317B1 (fr) * 2006-12-21 2009-02-13 Philippe Perovitch Forme galenique pour l'administration par voie transmuqueuse de paracetamol
CA2673049C (en) * 2006-12-22 2016-02-23 Novadel Pharma Inc. Stable anti-nausea oral spray formulations and methods
JP2010526054A (ja) * 2007-05-01 2010-07-29 シグモイド・ファーマ・リミテッド 併用医薬組成物
FR2947729B1 (fr) * 2009-07-10 2012-01-20 Philippe Perovitch Composition pharmaceutique pour le traitement du diabete de type ii par voie trans-muqueuse buccale

Also Published As

Publication number Publication date
JP2012513454A (ja) 2012-06-14
JP5529165B2 (ja) 2014-06-25
FR2940116B1 (fr) 2012-07-06
RU2528897C2 (ru) 2014-09-20
US8889663B2 (en) 2014-11-18
EP2379054A1 (fr) 2011-10-26
CN102264346A (zh) 2011-11-30
WO2010072950A1 (fr) 2010-07-01
RU2011130508A (ru) 2013-01-27
MX2011006797A (es) 2011-09-06
FR2940116A1 (fr) 2010-06-25
US20110257149A1 (en) 2011-10-20
BRPI0923675A8 (pt) 2018-05-29

Similar Documents

Publication Publication Date Title
EP2381773A4 (en) COMPOSITIONS FOR THE ADMINISTRATION OF MEDICINAL PRODUCTS
DK2692341T3 (da) Misbrugs-resistent lægemiddelformulering
DK2274030T4 (da) Lægemiddelafgivelsesanordning
IL249747A0 (en) Antibacterial oral composition
DK2328601T3 (da) Linaclotid-holdige formuleringer til oral indgivelse
DK2346495T4 (da) Farmaceutisk formulering 514
DK2381988T3 (da) Medikamentadministrationsanordning
ATE531410T1 (de) Arzneimittelabgabevorrichtung
DK2464342T3 (da) Farmaceutisk formulering mod stofmisbrug
IL207512A0 (en) Pharmaceutical composition for poorly soluble drugs
BRPI0908596A2 (pt) formulação e composição farmacêutica de liberação prolongada
DK2403569T3 (da) Lægemiddelafgivelsesanordning med tilbagetrækkelig nål
DK2296732T3 (da) Medikamentafgivelsesindretning
DK2274032T3 (da) Anordning til medicinindgivelse
EP2240022A4 (en) PHARMACEUTICAL COMPOSITIONS
BRPI0818680A2 (pt) composição farmacêutica, preparação farmacêutica, e método para preparar um forma de dosagem oral farmacêutica
BRPI0921654A2 (pt) formulação farmacêutica
BRPI0910901A2 (pt) composição farmacêutica com bisfosfonato
BRPI1007484A2 (pt) composição farmacêutica para administração oral
BRPI0923675A2 (pt) formulação para administração de medicamento com baixa quantidade de lipídeos por via transmucosal oral
BRPI0914971A2 (pt) composições farmacêuticas que contêm fármaco antibiótico de fluoroquinolonas
BRPI1007474A2 (pt) formulação para administração por via transmucosa oral de moléculas antálgicas e/ou antiespasmódicos.
BRPI0918539A2 (pt) preparação farmacêutica sólida para administração oral
EP2465512A4 (en) PAIN-SUBJECTIVE PHARMACEUTICAL COMPOSITION
EP2306998A4 (en) PHARMACEUTICAL FORMULATION

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B06T Formal requirements before examination
B07D Technical examination (opinion) related to article 229 of industrial property law

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notice of approval relating to section 229 industrial property law
B07A Technical examination (opinion): publication of technical examination (opinion)
B09B Decision: refusal
B09B Decision: refusal

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL